Table 4 Review all the studies concerning mutational analysis of primary PEACs
Study | No. of cases | Gene mutation | ||||||
|---|---|---|---|---|---|---|---|---|
KARS exon2-4 | EGFR exon 18-21 | EML4-ALK | BRAF exon15 | NRAS exon2-4 | ERBB2 (HER2) amplification/mutation | MMR | ||
Stojsic et al. [16] | 2 | 1+/1− | 2− | NA | NA | NA | NA | NA |
Lászlo et al. [17] | 1 | 1+ | 1− | NA | NA | NA | NA | NA |
Garajová et al. [18] | 2 | 2+ | 2− | 2− | NA | NA | NA | NA |
Metro et al. [19] | 1 | 1+ | NA | NA | NA | NA | NA | NA |
Lin et al. [21] | 1 | 1− | 1− | 1− | 1− | NA | NA | NA |
Wang et al. [15] | 9 | 9− | 9− | 9− | NA | NA | NA | NA |
Handa et al. [20] | 1 | NA | 1+ | NA | NA | NA | NA | NA |
Nottegar et al. [4] | 46 | 28+/18− | 1+/45− | 6+/40- | 46− | NA | NA | NA |
Matsushima et al. [22] | 7 | 1+/6− | 7− | NA | 7− | NA | NA | NA |
Nottegar et al. [5] | 8 | 4+/4− | 8− | 1+/7− | 8− | 8− | NA | NA |
The present study | 5 | 1+/4− | 1+/4− | 5− | 5− | 1+/4− | 2+/3− | 4+/1− |
Total | 39+/43− | 3+/79− | 7+/64− | 67− | 1+/12− | 2+/3− | 4+/1− | |
Incidence of mutation (%) | 47.6 | 3.7 | 9.9 | 0 | 7.7 | 40 | 80 | |